Literature DB >> 7913251

Gene therapy for infectious diseases: the AIDS model.

E Gilboa1, C Smith.   

Abstract

Genetic manipulation of somatic cells may be of therapeutic value in a variety of infectious diseases, particularly in human immunodeficiency virus (HIV) infection. Stable insertion of custom-designed 'resistance genes' into cells susceptible to HIV could reduce the viral burden in infected individuals and potentially retard the characteristic progressive immune dysfunction. Alternatively, ectopic expression of genes that encode viral antigens might induce potent antiviral immune responses and form the basis for novel prophylactic and therapeutic vaccines. While laboratory studies have proved that the approach works in principle, preclinical and clinical studies will be necessary to evaluate the therapeutic benefit of such gene-based therapies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913251     DOI: 10.1016/0168-9525(94)90216-x

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  18 in total

Review 1.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

2.  Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17.

Authors:  R Levin; A M Mhashilkar; T Dorfman; A Bukovsky; C Zani; J Bagley; J Hinkula; M Niedrig; J Albert; B Wahren; H G Göttlinger; W A Marasco
Journal:  Mol Med       Date:  1997-02       Impact factor: 6.354

Review 3.  Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.

Authors:  J A Smythe; G Symonds
Journal:  Inflamm Res       Date:  1995-01       Impact factor: 4.575

4.  Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

Authors:  S W Lee; H F Gallardo; E Gilboa; C Smith
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

Authors:  C M Browning; L Cagnon; P D Good; J Rossi; D R Engelke; D M Markovitz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures.

Authors:  G Schumann; L Qin; A Rein; G Natsoulis; J D Boeke
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.

Authors:  I Bahner; K Kearns; Q L Hao; E M Smogorzewska; D B Kohn
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.

Authors:  T VandenDriessche; M K Chuah; L Chiang; H K Chang; B Ensoli; R A Morgan
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Krüppel-associated box repressor domain targeted to the transactivating response element.

Authors:  G Pengue; A Caputo; C Rossi; G Barbanti-Brodano; L Lania
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.